Table 2 Treatments used for patients with IMIDs
From: COVID-19 vaccination of patients with chronic immune-mediated inflammatory disease
IMID diagnosis, n | Immunosuppressive treatments, n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
GC | MTX | TNFi | CsA | Lef | HCQ | JAKi | MMF | SSZ | |
All IMIDs, n = 158 | 80 (50.6) | 39 (24.7) | 38 (24. 1) | 7 (4.4) | 24 (15.2) | 69 (43.7) | 5 (3.2) | 16 (16.5) | 16 (10. 1) |
RA, n = 38 | 4 (10.5) | 30 (78.9) | 15 (39.5) | 0 | 24 (63.2) | 2 (5.3) | 5(13.2) | 0 | 2 (5.3) |
AS, n = 33 | 0 | 5 (15.2) | 23(69.7) | 0 | 0 | 0 | 0 | 0 | 14 (42.4) |
SLE, n = 77 | 70(90.9) | 3 (3.9) | 0 | 5 (6.5) | 0 | 60 (77.9) | 0 | 14 (18.2) | 0 |
pSS, n = 9 | 5 (55.6) | 0 | 0 | 2 (22.2) | 0 | 7 (77.8) | 0 | 2 (22.2) | 0 |
Others, n = 1 | 1 (100) | 1(100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |